Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06745323
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 444
- Registration Number
- NCT06700343
- Locations
- 🇺🇸
Profound Research - Neurology Center of Southern California, Carlsbad, California, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
🇺🇸Advanced Neurosciences Research, Llc, Fort Collins, Colorado, United States
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT06674941
- Locations
- 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 350
- Registration Number
- NCT06660173
- Locations
- 🇺🇸
New Horizon Research Center, Miami, Florida, United States
🇺🇸Florida Institute for Clinical Research, Orlando, Florida, United States
🇺🇸Conquest Research - Winter Park, Winter Park, Florida, United States
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT06649006
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 124
- Registration Number
- NCT06637371
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Translational Clinical Research LLC, Aventura, Florida, United States
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT06613100
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06598306
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Belgium
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06593522
- Locations
- 🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center, Duarte, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States